- Home
- ADAG vs IIF Comparison
ADAG vs IIF Comparison
Compare ADAG & IIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADAG | IIF |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | China | United States |
| Employees | 128 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.2M | 210.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADAG | IIF |
|---|---|---|
| Price | $3.23 | $22.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 187.3K | 23.0K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $19.83 |
| 52 Week High | $4.85 | $27.99 |
Technical Indicators
Market Signals| Indicator | ADAG | IIF |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 41.49 |
| Support Level | $3.23 | $22.29 |
| Resistance Level | $3.53 | $22.66 |
| Average True Range (ATR) | 0.27 | 0.18 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 34.20 | 34.62 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.